250 related articles for article (PubMed ID: 25979810)
1. γδ T cell activation by bispecific antibodies.
Oberg HH; Kellner C; Gonnermann D; Peipp M; Peters C; Sebens S; Kabelitz D; Wesch D
Cell Immunol; 2015 Jul; 296(1):41-9. PubMed ID: 25979810
[TBL] [Abstract][Full Text] [Related]
2. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.
Oberg HH; Peipp M; Kellner C; Sebens S; Krause S; Petrick D; Adam-Klages S; Röcken C; Becker T; Vogel I; Weisner D; Freitag-Wolf S; Gramatzki M; Kabelitz D; Wesch D
Cancer Res; 2014 Mar; 74(5):1349-60. PubMed ID: 24448235
[TBL] [Abstract][Full Text] [Related]
3. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
4. TCRVγ9 γδ T Cell Response to IL-33: A CD4 T Cell-Dependent Mechanism.
Duault C; Franchini DM; Familliades J; Cayrol C; Roga S; Girard JP; Fournié JJ; Poupot M
J Immunol; 2016 Jan; 196(1):493-502. PubMed ID: 26608919
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
[TBL] [Abstract][Full Text] [Related]
6. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
7. Human γδ T-cell responses in infection and immunotherapy: common mechanisms, common mediators?
Riganti C; Massaia M; Davey MS; Eberl M
Eur J Immunol; 2012 Jul; 42(7):1668-76. PubMed ID: 22806069
[TBL] [Abstract][Full Text] [Related]
8. Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
Ganesan R; Chennupati V; Ramachandran B; Hansen MR; Singh S; Grewal IS
Leukemia; 2021 Aug; 35(8):2274-2284. PubMed ID: 33526858
[TBL] [Abstract][Full Text] [Related]
9. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
10. Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens.
Iwasaki M; Tanaka Y; Kobayashi H; Murata-Hirai K; Miyabe H; Sugie T; Toi M; Minato N
Eur J Immunol; 2011 Feb; 41(2):345-55. PubMed ID: 21268005
[TBL] [Abstract][Full Text] [Related]
11. Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor human gammadelta T-cells.
Correia DV; d'Orey F; Cardoso BA; Lança T; Grosso AR; deBarros A; Martins LR; Barata JT; Silva-Santos B
PLoS One; 2009 May; 4(5):e5657. PubMed ID: 19479075
[TBL] [Abstract][Full Text] [Related]
12. Phosphoantigens overcome human TCRVgamma9+ gammadelta Cell immunosuppression by TGF-beta: relevance for cancer immunotherapy.
Capietto AH; Martinet L; Cendron D; Fruchon S; Pont F; Fournié JJ
J Immunol; 2010 Jun; 184(12):6680-7. PubMed ID: 20483742
[TBL] [Abstract][Full Text] [Related]
13. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
14. Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo.
Han H; Ma J; Zhang K; Li W; Liu C; Zhang Y; Zhang G; Ma P; Wang L; Zhang G; Tao H; Gao B
Int J Oncol; 2014 Dec; 45(6):2446-54. PubMed ID: 25242665
[TBL] [Abstract][Full Text] [Related]
15. Targeting γδ T lymphocytes for cancer immunotherapy: from novel mechanistic insight to clinical application.
Gomes AQ; Martins DS; Silva-Santos B
Cancer Res; 2010 Dec; 70(24):10024-7. PubMed ID: 21159627
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside.
Braza MS; Klein B
Br J Haematol; 2013 Jan; 160(2):123-32. PubMed ID: 23061882
[TBL] [Abstract][Full Text] [Related]
17. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
Miyashita M; Shimizu T; Ashihara E; Ukimura O
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
[TBL] [Abstract][Full Text] [Related]
18. γδ T-APCs: a novel tool for immunotherapy?
Moser B; Eberl M
Cell Mol Life Sci; 2011 Jul; 68(14):2443-52. PubMed ID: 21573785
[TBL] [Abstract][Full Text] [Related]
19. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
[TBL] [Abstract][Full Text] [Related]
20. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
